Deutsch English Français

Contact

EP2315846

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2315846

EP2315846 - PSA AND KLK2 AS THERAPEUTIC TARGETS AND MOLECULES INHIBITING PSA AND KLK2 [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 08.11.2013 Database last updated on 03.10.2024
Most recent event Tooltip	08.11.2013	Application deemed to be withdrawn	published on 11.12.2013 [2013/50]
Applicant(s)	For all designated states University of Rochester 601 Elmwood Avenue Box OTT Rochester, NY 14642 / US
	[N/P]
Former [2011/18]	For all designated states University Of Rochester 601 Elmwood Avenue Box OTT Rochester, NY 14642 / US
Inventor(s)	01 / CHANG, Chawnshang 19 Sandy Lane Pittsford, NY 14534 / US
	[2011/18]
Representative(s)	Leißler-Gerstl, Gabriele Hoefer & Partner Patentanwälte mbB Pilgersheimer Strasse 20 81543 München / DE
	[N/P]
Former [2011/18]	Leissler-Gerstl, Gabriele Hoefer & Partner Patentanwälte Pilgersheimer Strasse 20 81543 München / DE
Application number, filing date	09805479.4	05.08.2009
	[2011/18]
	WO2009US52779
Priority number, date	US20080086461P	05.08.2008 Original published format: US 86461 P
	US20080093285P	29.08.2008 Original published format: US 93285 P
	US20080093353P	31.08.2008 Original published format: US 93353 P
	[2011/18]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2010017257
	Date:	11.02.2010
	Language:	EN
	[2010/06]
	Type:	A2 Application without search report
	No.:	EP2315846
	Date:	04.05.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 11.02.2010 takes the place of the publication of the European patent application.
	[2011/18]
Search report(s)	International search report - published on:	US	20.05.2010
	(Supplementary) European search report - dispatched on:	EP	28.10.2011
Classification	IPC:	C12Q1/68, G01N33/50, G01N33/574	[2011/47]
	CPC:	G01N33/5011 (EP,US); C12Q1/6886 (EP,US); G01N33/574 (EP,US); G01N33/57434 (EP,US); C12Q2600/136 (EP,US); C12Q2600/158 (EP,US); (+) G01N2333/96455 (EP,US); G01N2500/02 (EP,US) (-)
	Former IPC [2011/18]	C12Q1/68
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2011/18]
Title	German:	PSA UND KLK2 ALS THERAPEUTISCHE ZIELMOLEKÜLE SOWIE PSA- UND KLK2-HEMMENDE MOLEKÜLE	[2011/18]
	English:	PSA AND KLK2 AS THERAPEUTIC TARGETS AND MOLECULES INHIBITING PSA AND KLK2	[2011/18]
	French:	PSA ET KLK2 EN TANT QUE CIBLES THÉRAPEUTIQUES ET MOLÉCULES INHIBANT PSA ET KLK2	[2011/18]
Entry into regional phase	01.03.2011	National basic fee paid
	01.03.2011	Search fee paid
	01.03.2011	Designation fee(s) paid
	01.03.2011	Examination fee paid
Examination procedure	01.03.2011	Examination requested [2011/18]
	25.05.2012	Amendment by applicant (claims and/or description)
	19.02.2013	Despatch of a communication from the examining division (Time limit: M04)
	02.07.2013	Application deemed to be withdrawn, date of legal effect [2013/50]
	07.08.2013	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2013/50]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 19.02.2013
Fees paid	Renewal fee
	25.08.2011	Renewal fee patent year 03
	27.08.2012	Renewal fee patent year 04
	Penalty fee
	Additional fee for renewal fee
	31.08.2013	05 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XY]US2005112705 (BRACCO LAURENT [FR], et al) [X] 10,11,13,14 * par 0001-0002, 0010, 0044, 0076-0083, 0085, 0087-0088; cl 25, 27, 29, 44-46. * [Y] 1-9,12;
		[XYI]US2003054053 (YOUNG CHARLES [US], et al) [X] 10,11,13,14 * par 0007, 0011, 0023, 0035-0037, 0049, 0051, 0060, 0067; Fig. 2; cl 17-20 * [Y] 12 [I] 2-4,6,7,9;
		[I]US2003055108 (YOUNG CHARLES [US]) [I] 2-4,6,7,9 * par 0006, par 0044, cl 13-15. *;
		[Y]US2006270591 (CHANG CHAWNSHANG [US]) [Y] 1,3-9,12 * par 0004, 0057, 0066, 0171, 0519. *
		[X] - CHEN SOPHIE ET AL, "Down-regulation of androgen-receptor and PSA by phytochemicals.", INTERNATIONAL JOURNAL OF ONCOLOGY FEB 2008 LNKD- PUBMED:18202763, (200802), vol. 32, no. 2, ISSN 1019-6439, pages 405 - 411, XP002660757 [X] 2-4,6,7,9 * pg 405-411. *
		[Y] - NIU Y ET AL, "Prostate-Specific Antigen Promote Prostate Cancer Cell Growth via Modulating Androgen Receptor Activation", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, (20070520), vol. 177, no. 4 supplement, ISSN 0022-5347, page 89, XP008143258 [Y] 1-9,12 * the whole document *
	International search	[Y]US2006074026 (HAZEN STANLEY L [US], et al);
		[Y]US2007149469 (KORHERR CHRISTIAN [DE]);
		[Y]US2006270591 (CHANG CHAWNSHANG [US])
		[Y] - NIU, Y. ET AL., "Prostate-Specific Antigen Promote Prostate Cancer Cell Growth via Modulating Androgen Receptor Activation.", JOURNAL OF UROLOGY, vol. 177, no. 4,SUPP, page 89, XP008143258

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p